Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
Author:
Affiliation:
1. La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/jm2007613
Reference64 articles.
1. The discovery of receptor tyrosine kinases: targets for cancer therapy
2. Tyrosine Kinases as Targets for Cancer Therapy
3. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition
4. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
Cited by 810 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Design, synthesis and pharmacological evaluation of novel thiazole derivatives as c-Met kinase inhibitors and anticancer agents;Journal of Molecular Structure;2024-12
2. ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals;Current Problems in Cancer;2024-12
3. Manganese catalyzed asymmetric transfer hydrogenation of hindered ketones bearing a 2,6-disubstituted phenyl group;Journal of Catalysis;2024-10
4. Hit me with your best shot: Integrated hit discovery for the next generation of drug targets;Drug Discovery Today;2024-10
5. Azole‐Substituted Triazole Formation through Organocatalytic Cycloaddition of β‐keto Azoles and Aryl Azides;ChemistrySelect;2024-09-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3